I-FDA igunyaza i-ibrutinib yokwelapha isifo esingamahlalakhona sokuxhunyelelwa ngokumelene ne-host (cGVHD) ezinganeni

Ngomhla zingama-24 ku-Agasti, 2022, i-US Food and Drug Administration (FDA) igunyaze i-ibrutinib yokwelapha iziguli zezingane ezindala kunonyaka ongu-1 ezine-graft-versus-host disease ( cGVHD ) ezithola Ngemva kokuhluleka kwe-1- noma imigqa eminingi ukwelashwa kwesistimu .Inkomba egunyaziwe ikakhulukazi eyeziguli zezingane, nezinga lokuphendula lilonke elingu-60% evikini lama-25, futhi ukwakheka kwemithi kuhlanganisa amaphilisi, amaphilisi kanye nokulengiswa ngomlomo.

I-Ibrutinib, i-BTK inhibitor eyakhiwe ngokubambisana yi-Pharmacicics/Johnson & Johnson, iyi-kinase inhibitor eyagunyazwa ngaphambilini ukwelapha i-lymphocytic leukemia engapheli kanye ne-cell lymphoma nezinye izifo.

I-Suntech igxile ekuthuthukisweni nasekukhiqizweni kwama-intermediate emithi kanye nama-API esebenzisa ubuchwepheshe obuluhlaza.Njengamanje, inkampani yethu ithuthukise imikhiqizo emithathu emaphakathi ye-ibrutinib ehlanganisa i-C AS: 143900-44-1 , C AS: 330792-70-6 , C AS: 330786-24-8 , yonke eye yathengiswa ekukhiqizeni amafektri e-GMP. .Phakathi kwabo, okuphakathi kwe-C AS: 143900-44-1 kukhiqizwa ubuchwepheshe be-chemical-enzymatic , enezinzuzo zokuvikelwa kwemvelo okuluhlaza, intengo ephansi kanye nekhwalithi ephezulu.Siyakwamukela ukubonisana nokubambisana!